Keytruda – Genprex

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Keytruda® to Treat Non-Small Cell Lung Cancer

March 31, 2022Kalyn Dabbs Acclaim 2 Press Releases

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Keytruda® to Treat Non-Small Cell Lung Cancer

Company Has FDA Fast Track Designation for Combination of REQORSA and Keytruda

Designed and Secured by Barsec

Copyright ©2024 all rights reserved.
Home - Privacy Policy - Terms of Use